Adipotide (Fat-Targeted Proapoptotic Peptide) 5mg

Adipotide is an experimental peptide that, in a research context, attracts serious interest with its targeted approach to adipose tissue and its potential to assist fat reduction through a mechanism different from classical fat loss approaches. This makes it one of the most interesting and unconventional peptides in obesity and body composition research.

What is Adipotide?

Adipotide, also known as fat-targeted proapoptotic peptide, is an experimental peptide agent designed to target the blood vessels that feed white adipose tissue. Instead of acting by suppressing appetite, directly stimulating lipolysis, or hormonal control, Adipotide was developed to attack the vascular network of adipose tissue, leading to damage of fat cells and subsequent reduction of fat depots.

The peptide is associated with research on a protein called prohibitin, which is expressed in the vasculature of adipose tissue. It is through this targeting that Adipotide differs from almost all other fat-reduction peptides. Instead of a “general” action on metabolism, it was created to act selectively on adipose tissue.

This is also the main reason it has generated serious interest in scientific circles. In animal models Adipotide has shown the ability to lead to marked loss of fat mass and body weight, including in obese rhesus monkeys, where significant weight reduction and improvement in metabolic parameters were observed.

Adipotide is not approved as a medicinal product by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Available data are mainly from preclinical studies and animal models.

What are the benefits of Adipotide?

• Targeting adipose tissue

Adipotide is developed to act selectively on the blood vessels of white adipose tissue, which sets it apart from standard fat loss approaches.

• Reduction of body fat

In studies on animal models, a significant reduction in fat mass and body weight has been observed.

• Improvement of body composition

The peptide is considered a tool for a more aggressive and targeted effect on fat depots, especially in obesity.

• Different mechanism from classic fat burners

Adipotide does not rely primarily on stimulants, thermogenesis, or appetite suppression, but on direct targeting of adipose tissue.

• Research interest in obesity studies

Because of its mechanism of action, Adipotide remains one of the most interesting experimental peptides in scientific research on obesity and metabolic disorders.

Clinical trials on Adipotide

Adipotide is strongest mainly in its preclinical profile. Published studies in mice, rats, and monkeys show substantial weight loss, reduction of adipose tissue, and improvement in some metabolic markers. In dose-finding studies in monkeys, pronounced body weight reduction was reported, which made the peptide particularly well-known in the research world.

At the same time, there is an important caveat. In non-human primates reversible kidney toxicity was reported, which is one of the main factors that limited its further development. There are also review sources stating that the first human clinical trial was terminated in 2019 for unspecified reasons.

This means that Adipotide is interesting and strong as a concept, but it is not a peptide with an established clinical profile or an approved medical application. From a product standpoint it is positioned as a niche, high-risk, and highly experimental peptide.

Administration and dosage of the peptide Adipotide (FTPP) within a research protocol

In scientific research Adipotide is administered in low, targeted amounts for a limited period of time. The focus is on selectivity and efficacy, not on high doses or prolonged use. This approach allows measurable results while maintaining overall balance in the organism.

The most common indicative research regimens include doses of 150–200 mcg daily, divided into 1–2 administrations. The duration of cycles most often varies between 2 and 4 weeks, with shorter duration preferred due to the peptide’s specific mechanism of action.

Possible side effects of Adipotide (FTPP)

As with all research peptides, individual response can vary. In the available research data adverse reactions are rare and usually transient, especially with short-term and controlled use.

In some cases the following have been observed:

• temporary feelings of fatigue
• mild general discomfort at the beginning of the protocol
• transient changes in metabolic markers with prolonged use

Due to its specific mechanism, Adipotide is used only in clearly defined research protocols with the aim of maximal precision and control.

Comparison of Adipotide with other peptides

Adipotide belongs to the group of metabolically targeted experimental peptides, but it stands out with a completely different mechanism compared to most products in this category. Instead of primarily affecting hormones, appetite, or lipolysis, it is being studied for targeted impact on the blood vessels that support adipose tissue.

Adipotide vs AOD-9604

AOD-9604 is mainly associated with lipolysis and fat metabolism, without significant impact on classic GH pathways. Adipotide works by a different model, targeting the vasculature of adipose tissue. In short, AOD-9604 aims to break down fat, while Adipotide aims to limit the support of adipose tissue.

Adipotide vs HGH Fragment 176-191

The fragment peptide is aimed at stimulating lipolysis and improving body composition through mechanisms associated with the GH fragment. Adipotide does not act through this pathway, but through vascular targeting of adipose tissue.

Adipotide vs CJC-1295 / Ipamorelin

CJC-1295 and Ipamorelin stimulate the natural release of growth hormone, which more broadly affects metabolism, recovery, and body composition. Adipotide does not stimulate the GH axis and does not rely on a hormonal mechanism, but on direct targeting of adipose tissue.

Adipotide vs Retatrutide

Retatrutide is a multi-receptor incretin agonist that mainly acts by controlling appetite, slowing gastric emptying, improving glucose metabolism, and increasing energy expenditure. Adipotide works by a completely different model. It does not rely on appetite suppression or incretin pathways, but is being studied for direct targeting of the blood vessels that support adipose tissue.

The information on this website has been collected and summarized from multiple scientific studies and analyses.

It is entirely informational and is not intended for diagnosis, treatment, or prevention of diseases.

The products offered on the site are not classified as drugs or medical devices and are suitable only for laboratory and scientific research purposes.